

Down-Regulation of *PU.1* Gene in Pediatric Acute Lymphoblastic Leukemia Patients from South of Iran

Bitā Nakhost¹, Mahboobeh Nasiri¹, Mehran Karimi², Somayeh Montazeri³

¹Department of Biology, Islamic Azad University, Arsanjan Branch, Arsanjan, Iran

²Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

³Thalassemia and Hemophilia Genetic, PND Research Center, Dastgheib Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Corresponding Author: Mahboobeh Nasiri, Department of Biology, Islamic Azad University, Arsanjan Branch, Arsanjan, Iran

Tel: 7376153161

Fax: 43522483

Email: nasiri@iaua.ac.ir

Received: 02, Mar, 2018

Accepted: 10, Nov, 2018

ABSTRACT

Background: Acute lymphoblastic leukemia (ALL) is resulted from the infiltration of high amount of non-differentiated cells in bone marrow. Differentiation of the hematopoietic stem cells into specific cell lineage occurs through a highly regulated pathway which is mainly monitored during transcription step. Expression level and pattern of transcription factors e.g. *PU.1* determine fate and developmental phases in this pathway. This study was performed to evaluate the expression level of the *PU.1* gene in a group of children suffering from ALL.

Materials and Methods: The mRNA expression level of the *PU.1* gene was compared between 30 children diagnosed as new cases of ALL and 30 sex- and gender-matched healthy children in the present case-control study. The quantitative real time PCR (qRT-PCR) was used to determine the level of *PU.1* gene expression. The data were analyzed using Graph Pad Prism statistical software.

Results: The mRNA level of the *PU.1* gene was significantly lower in the blood samples of the ALL patients compared to the controls ($p=0.002$).

Conclusion: The results of the study indicated that the *PU.1* gene seemed to have key roles in the differentiation pathway of blood cells.

Keywords: Pediatric ALL; *PU.1*; Gene expression

INTRODUCTION

All blood cell types originate from multi-potent hematopoietic stem cells (HSCs) through a highly orchestrated process, called hematopoiesis¹. Any disturbance in this highly conserved critical process deregulated the cell decision for proliferation or differentiation which may result in human cancers such as leukemia². Among all types of leukemia,

acute lymphoblastic leukemia (ALL) is the most common malignancy in young children. It is characterized by a block of B- and T-cell differentiation and the accumulation of immature B and T lymphoblast, which are called B-lymphoblastic ALL and T-cell ALL, respectively³. Transcriptional regulation seems crucial for maintaining the sequential stages of the

hematopoiesis since involving in the programming of cell fate and their lineage commitment by regulating lineage-specific gene expression^{4,5}. The transcription factor, purine-rich box1 (PU.1 or Spi-1), belongs to the E26 transformation-specific (ETS) family and shows to have a critical role in the health of hematopoiesis⁶. *PU.1* gene is differentially expressed in various hematopoietic cells and regulates hematopoiesis in dose-dependent manner⁶. The expression level of *PU.1* represents an ascending gradient toward the development of lymphoblast to mature B-cells, but shows attenuation toward the more committed T cells⁷⁻⁹. Regarding previous reports on the influence of altered expression of *PU.1* on erythroleukemia¹⁰ and myeloid leukemia¹¹, we aimed to clarify whether the *PU.1* gene expression modification affects B- and T-cell lymphopoiesis and involves in acute lymphoblastic leukemia (ALL) malignancy.

MATERIALS AND METHODS

Subjects

This case-control study included 30 new cases of pediatric ALL (mean \pm SD: 8.03 \pm 3.99 years; 2-17 years) hospitalized in Amir Oncology Hospital, Shiraz, Iran. Twenty-one out of 30 patients were diagnosed as having B- lymphoblastic ALL and the 9 remaining patients were diagnosed with T-cell ALL. Immunology and cytogenetic tests and microscopic observation of the cell morphology were used to confirm the diagnosis. Patients with the age more than 20 years, personal history of any bleeding disorders or other malignancies, history of radiotherapy or chemotherapy at the time of sampling or earlier time, and relapsed ALL were excluded from the study. Thirty healthy subjects (7.86 \pm 4.15 years) matched by age and gender were also investigated as a control group. According to all parents in an oral interview, none of the children had prior history of malignancies or bleeding disorders. Written informed consent was signed by all parents (cases and controls) and the procedures of the project were definitely explained to those parents who were interested in detailed information. The study was approved by the Institutional Review Board of our department.

RNA extraction, cDNA synthesis, and Real-Time PCR analysis

Total RNA was extracted from 2-4 ml of fresh blood using RNX-Plus solution (CinnaGen, Iran) following the manufacturer's protocol. cDNA was synthesized using RevertAid first-strand cDNA synthesis kit (Thermo Scientific Fermentas, USA) according to the manufacturer's instructions. Primer pairs for *PU.1* and TATA-binding protein (*TBP*) as an internal control gene were designed by Allele ID v7.8 software. Primer sequences were as follows: forward, 5'-TTACCCCTATCTCAGCAG-3' and reverse, 5'-GAAGTTGTTCTCGGCGAAG-3' for *PU.1* gene; and forward, 5'-CCCAGAACGCCGAATATAAT-3' and reverse, 5'-CTGGACT GTTCTTCACTCT TG-3' for *TBP* gene. The quantitative real-time PCR was performed in the Rotor-Gene Q 2plex HRM Platform real-time PCR system (Corbett Life Science) machine in the volume of 15 μ l containing 7.5 μ l of 2x SYBR-Green master mix (Yekta Tajhiz Azma, Iran), 5 μ l of cDNA, 0.4 μ l and 1.5 μ l of each primer pair for *TBP* and *PU.1* genes. All reactions were done in duplicate. The PCR condition was as follows: initial denaturation at 95°C for 15 min followed by 40 cycles of denaturation at 95°C for 15 s; annealing at 58°C for 60 s and extension at 72°C for 60 s. The Threshold Cycle (CT) values were determined and the relative expression levels of the target gene were normalized to the expression levels of the endogenous control gene, *TBP*. The data were analyzed using the comparative threshold cycle ($2^{-\Delta\Delta CT}$) method.

Statistical analysis

Expression level difference was evaluated using GraphPad Prism statistical software (La Jolla, USA). Unpaired t-test was used to show the difference in gene expression between cases and controls. Nominal variables were presented as mean \pm standard deviation (SD). The numbers and percentages were directly calculated and presented for each of the categorical variables, and then compared between cases and controls using Pearson Chi-square test. The *p*-value equivalent or less than 0.05 was considered statistically significant for all types of analyses.

RESULTS

Baseline characteristics of the study population are presented in Table 1. The disease was more frequent in males than in females (63.3% vs. 36.7%).

Table 1. General characteristics of the study population

Characteristics	Controls	ALL cases
Number	30	30
Age (mean±SD; years)	7.86± 4.15	8.03± 3.99
Gender (M/F)	19/11	19/11
ALL type		
B-lymphoblastic	-	21
T-ALL	-	9

PU.1 gene expression analysis

Comparison of the expression level of the *PU.1* gene between children with ALL and healthy children resulted in the significant difference ($p=0.002$). The reduced expression level of *PU.1* gene was observed in ALL group compared with the control group (Figure 1).




Figure 1. Expression status of *PU.1* gene in ALL patients and controls

DISCUSSION

To the best of our knowledge, this is the first report of investigating the expression level of *PU.1* gene in pediatric ALL patients in Iran. The results are more considerable since all the ALL patients were described as new cases. Down-regulation of *PU.1* gene in our patients creates new insight into the importance of transcription regulation in the pathogenesis of ALL and introduces this gene as a

probable molecular target in designing new treatment strategies.

Normal hematopoiesis is securely controlled by a small number of lineage-specific transcription factors, so that the disturbed expression or function of this group may be involved in the development of leukemia¹². *PU.1* acts as an upstream regulator for the transcription factors c-Jun and b-Jun¹³. Multiple knockdown models have demonstrated the importance of *PU.1* gene in the susceptibility to ALL¹¹, while more frequency of myeloid leukemia has been seen in *PU.1*-deficient adult mice¹⁴. Evaluating the pre-leukemic hematopoietic stem cells (pHSCs) transcript in response to *PU.1* knockdown resulted in the obvious changes in the c- and b-Jun transcription factors¹³. Polgárová et al. (2016) recently published a list, containing 90 regulatory and differentiation-related genes e.g. *PU.1* for their involvement in the human hematopoiesis¹⁵. Despite previous studies on the reduced expression of the *PU.1* gene in the CML patients, the direct investigation of *PU.1* mRNA level in the blood samples of the ALL patients was not performed^{16, 17}. But the reduced *PU.1* expression was evaluated in bone marrow cells of ALL patients and the related mice models, with a presumption of AML1-ETO involvement¹⁸ or Notch signaling¹⁹. Heterozygous deletion of the *PU.1* locus was supposed to be associated with human AML. In two distinct studies, 126 and 120 AML patients were analyzed using direct sequencing^{20,21}. Quantitative real-time PCR; however, revealed a decrease in gene expression²¹. Aside from mutations, a SNP in a distal enhancer of *PU.1* gene was also reported a reduction in the *PU.1* gene expression²². Although it was out of our research scope to look for rare *PU.1* mutations in human samples, the lower expression of the gene was observed in our study. A similar finding was also observed in acute promyelocytic leukemia (APL) and considered to be in correlation with APL initiation²³ and progression²⁴. The most recent attempt for elucidating the mechanism of *PU.1* protein provided this idea that *PU.1* supports TRAIL-induced cell death by affecting an NF-κB-related pathway in AML²⁵, or a trichostatin A-induced apoptosis in collaboration with Bim during lymphoma²⁶. We suggest other researchers share their clinical data

along with their genetic analysis for *PU.1* and other newly discovered genes. Here, we reported that the transcriptional level of *PU.1* gene is significantly lower in Iranian pediatric patients with ALL, and more studies with larger sample sizes are required to confirm this finding by providing novel *PU.1* associated mechanisms.

ACKNOWLEDGMENT

The authors would like to express their gratitude to Mr. Tavafoghi for his special assistant in blood sampling and preparing the reagents for experimental procedures. The data presented here were extracted from the MSc thesis of the Bita Nakhost as a graduate student of Molecular Genetics from Islamic Azad University, Arsanjan Branch.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Rieger MA, Schroeder T. Hematopoiesis. Cold Spring Harb Perspect Biol. 2012; 4 (12).
- Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res. 1998; 22(12): 1085-96.
- Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617): 1030-43.
- Wilkinson AC, Göttgens B. Transcriptional regulation of haematopoietic stem cells. Adv Exp Med Biol. 2013; 786: 187-212.
- Mak KS, Funnell AP, Pearson RC, et al. *PU.1* and Haematopoietic Cell Fate: Dosage Matters. Int J Cell Biol. 2011; 2011: 808524.
- Iwasaki H, Somoza C, Shigematsu H, et al. Distinctive and indispensable roles of *PU.1* in maintenance of hematopoietic stem cells and their differentiation. Blood. 2005; 106(5): 1590-600.
- Back J, Allman D, Chan S, et al. Visualizing *PU.1* activity during hematopoiesis. Exp Hematol. 2005; 33(4): 395-402.
- Nutt SL, Metcalf D, D'Amico A, et al. Dynamic regulation of *PU.1* expression in multipotent hematopoietic progenitors. J Exp Med. 2005; 201(2): 221-31.
- Klemsz MJ, McKercher SR, Celada A, et al. The macrophage and B cell-specific transcription factor *PU.1* is related to the *ets* oncogene. Cell. 1990; 61(1): 113-24.
- Blaybel R, Théoleyre O, Douablin A, et al. Downregulation of the *Spi-1/PU.1* oncogene induces the expression of *TRIM10/HERF1*, a key factor required for terminal erythroid cell differentiation and survival. Cell Res. 2008; 18(8): 834-45.
- Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, *PU.1*. Nat Genet. 2004; 36(6): 624-30.
- Koschmieder S, Rosenbauer F, Steidl U, et al. Role of transcription factors *C/EBP α* and *PU.1* in normal hematopoiesis and leukemia. Int J Hematol. 2005; 81(5): 368-77.
- Steidl U, Rosenbauer F, Verhaak RG, et al. Essential role of Jun family transcription factors in *PU.1* knockdown-induced leukemic stem cells. Nat Genet. 2006; 38(11): 1269-77.
- Metcalf D, Dakic A, Mifsud S, et al. Inactivation of *PU.1* in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103(5): 1486-91.
- Polgárová K, Vášková M, Froňková E, et al. Quantitative expression of regulatory and differentiation-related genes in the key steps of human hematopoiesis: The LeukoStage Database. Differentiation. 2016; 91(1-3): 19-28.
- Mankaï A, Bordron A, Renaudineau Y, et al. Purine-rich box-1-mediated reduced expression of *CD20* alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. Cancer Res. 2008; 68(18): 7512-9.
- Albajar M, Gutierrez P, Richard C, et al. *PU.1* expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008; 270(2): 328-36.
- Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor *PU.1* is inactivated by *AML1-ETO* in t (8; 21) myeloid leukemia. Blood. 2003; 101(1): 270-7.
- Chen PM, Yen CC, Wang WS, et al. Down-regulation of *Notch-1* expression decreases *PU.1*-mediated myeloid differentiation signaling in acute myeloid leukemia. Int J Oncol. 2008; 32(6): 1335-41.
- Mueller BU, Pabst T, Osato M, et al. Heterozygous *PU.1* mutations are associated with acute myeloid leukemia. Blood. 2002; 100(3): 998-1007.
- Bonadies N, Pabst T, Mueller BU. Heterozygous deletion of the *PU.1* locus in human AML. Blood. 2010; 115(2): 331-4.
- Steidl U, Steidl C, Ebralidze A, et al. A distal single nucleotide polymorphism alters long-range regulation of the *PU.1* gene in acute myeloid leukemia. J Clin Invest. 2007; 117(9): 2611-20.
- Zhu X, Zhang H, Qian M, et al. The significance of low *PU.1* expression in patients with acute promyelocytic leukemia. J Hematol Oncol. 2012; 5: 22.

24. Wei S, Zhao M, Wang X, et al. PU. 1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. *J Hematol Oncol.* 2016; 9(1): 44.
25. Haimovici A, Humbert M, Federzoni EA, et al. PU. 1 supports TRAIL-induced cell death by inhibiting NF- κ B-mediated cell survival and inducing DR5 expression. *Cell Death Differ.* 2017; 24(5): 866-877.
26. Li C, Tao Y, Li C, et al. PU. 1–Bim axis is involved in Trichostatin A-induced apoptosis in murine pro-B lymphoma FL5. 12 cells. *Acta Biochim Biophys Sin (Shanghai).* 2016;48(9):850-5.